Healthcare

UAE investment drives AI-enabled biopharma transformation

A report detailed UAE investment in AI-driven drug discovery, genomics, precision medicine, and biopharmaceutical manufacturing.

A World Health Expo and Frost & Sullivan report examined how UAE investment in genomics, AI, and advanced manufacturing is reshaping regional biopharmaceutical development. The report said AI is increasingly being used to identify drug candidates, design clinical trials, and improve production. It also cited Insilico Medicine’s Abu Dhabi center, which nominated the UAE’s first fully AI-discovered preclinical candidates for oncology and non-opioid pain in 2025 after completing discovery workflows in under 12 months. The report linked these developments to growth in precision medicine across the Middle East. AI-based drug discovery matters because it can shorten parts of the research process and help pharmaceutical companies evaluate more candidates. The source presents the UAE as an emerging regional hub, while the cited candidates remain preclinical and are not evidence of approved treatments.

Original source: Pharmaphorum

Related RAQI solutions

In-depth analysis on RAQI Insight

Work with RAQI